Bioventus BVS U.S. Segment — Adjusted cost of sales

Similar metrics at other companies

UEICReportable Segment — Adjusted cost of sales

$47.32M-30.9%

JEL

JELDEurope — Adjusted cost of sales

$217.26M+9.8%

SMGHawthorne — Adjusted cost of sales

$32.4M-49.9%

TILEAMS — Adjusted cost of sales

$125.72M-6.9%

TILEEAAA — Adjusted cost of sales

$91.9M+0.8%

MLKNGlobal Retail — Adjusted cost of sales

$162M+7.3%

FAQ

What is Bioventus's U.S. segment — adjusted cost of sales?

Bioventus (BVS) reported U.S. segment — adjusted cost of sales of $30.97M in Q2 2026.

How has Bioventus's U.S. segment — adjusted cost of sales changed year-over-year?

Bioventus's U.S. segment — adjusted cost of sales increased by 9.7% year-over-year, from $28.22M to $30.97M.

What is the long-term trend for Bioventus's U.S. segment — adjusted cost of sales?

Over 3 years (2022 to 2025), Bioventus's U.S. segment — adjusted cost of sales has grown at a 1.2% compound annual growth rate (CAGR), from $109.96M to $113.82M.

What does U.S. segment — adjusted cost of sales mean?

This metric captures the direct costs associated with producing and delivering medical products sold within the U.S. segment, excluding non-recurring or non-operational charges. Monitoring this helps evaluate the efficiency of the supply chain and manufacturing processes for the domestic business.